Seroatlas · Human Serome Atlas

PSMB9

Proteasome subunit beta type-9

Also known as: beta1i, LMP2, PSB9_HUMAN, PSMB6i, RING12

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P28065
Gene
PSMB9
Ensembl
ENSG00000240065
Chromosome
6
Canonical length
219 aa
Protein class
Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location
Cytosol

OverviewNCBI Gene

The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 1 (proteasome beta 6 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. [provided by RefSeq, Mar 2010]

Canonical amino-acid sequenceUniProt

219 residues, UniProt reviewed canonical sequence.

>P28065|PSMB9
     1  MLRAGAPTGD LPRAGEVHTG TTIMAVEFDG GVVMGSDSRV SAGEAVVNRV FDKLSPLHER
    61  IYCALSGSAA DAQAVADMAA YQLELHGIEL EEPPLVLAAA NVVRNISYKY REDLSAHLMV
   121  AGWDQREGGQ VYGTLGGMLT RQPFAIGGSG STFIYGYVDA AYKPGMSPEE CRRFTTDAIA
   181  LAMSRDGSSG GVIYLVTITA AGVDHRVILG NELPKFYDE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PSMB9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.29
Highest tissue expression
140 nTPM

Expression across tissuesHPA

Tissue

  • spleen: 140 nTPM
  • small intestine: 66 nTPM
  • lung: 53 nTPM
  • adipose tissue: 41 nTPM
  • breast: 36 nTPM
  • colon: 34 nTPM

Single-cell type

  • enterocytes: 240 nCPM
  • gastric progenitor cells: 215 nCPM
  • cdc: 120 nCPM
  • nk-cells: 119 nCPM
  • pdcs: 117 nCPM
  • t-cells: 114 nCPM

Immune cell

  • neutrophil: 97 nTPM
  • basophil: 93 nTPM
  • eosinophil: 76 nTPM
  • NK-cell: 62 nTPM
  • non-classical monocyte: 61 nTPM
  • T-reg: 61 nTPM

Brain region

  • medulla oblongata: 12 nTPM
  • pons: 8.4 nTPM
  • white matter: 8.1 nTPM
  • hypothalamus: 7.9 nTPM
  • spinal cord: 7.8 nTPM
  • thalamus: 7 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PSMB9.

Disease | AllUniProt

Conditions PSMB9 is implicated in, by any mechanism.

  • Proteasome-associated autoinflammatory syndrome 3 (PRAAS3) MIM:617591
  • Proteasome-associated autoinflammatory syndrome 6 (PRAAS6) MIM:620796

Disease | GeneticClinVar

2 pathogenic / likely-pathogenic of 63 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Proteasome-associated autoinflammatory syndrome 6
  • proteasome-associated autoinflammatory syndrome with immunodeficiency (PRAAS-ID)

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.96
gnomAD pLI
0
gnomAD missense Z
0.93
DepMap mean gene effect
0.05
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PSMB9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PSMB9 as an antibody target. Whether an autoantibody or antibody against PSMB9 could matter depends on whether native PSMB9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PSMB9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PSMB9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PSMB9. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...